ETC
ZNTL icon

Exchange Traded Concepts’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Exchange Traded Concepts’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67,401
Closed -$107K – 1519
2025
Q1 		$107K Buy
67,401
+21,895
+48% +$47.2K ﹤0.01% 1137
2024
Q4 		$138K Hold
45,506
– – ﹤0.01% 1081
2024
Q3 		$167K Buy
45,506
+30,098
+195% +$109K ﹤0.01% 1018
2024
Q2 		$63K Sell
15,408
-4,793
-24% -$53.5K ﹤0.01% 973
2024
Q1 		$318K Buy
20,201
+14,212
+237% +$195K 0.01% 777
2023
Q4 		$90.7K Buy
5,989
+1,519
+34% +$22.2K ﹤0.01% 898
2023
Q3 		$89.7K Sell
4,470
-1,184
-21% -$30.1K ﹤0.01% 939
2023
Q2 		$159K Buy
+5,654
New +$136K ﹤0.01% 830

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Exchange Traded Concepts's ZNTL Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 67,401 shares — an estimated $107K sold.

Exchange Traded Concepts first reported a position in ZNTL in Q2 2023 and held it in 8 quarters. The position peaked at $318K in Q1 2024. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 67,401 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $107K.
  • Exchange Traded Concepts first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Zentalis Pharmaceuticals position peaked at $318K in Q1 2024.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.